Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Payables (2016 - 2025)

BioCorRx's Payables history spans 16 years, with the latest figure at $13.9 million for Q3 2025.

  • For Q3 2025, Payables rose 100.12% year-over-year to $13.9 million; the TTM value through Sep 2025 reached $13.9 million, up 100.12%, while the annual FY2024 figure was $6.9 million, 31.62% up from the prior year.
  • Payables for Q3 2025 was $13.9 million at BioCorRx, up from $13.4 million in the prior quarter.
  • Across five years, Payables topped out at $13.9 million in Q3 2025 and bottomed at $1.5 million in Q1 2023.
  • The 5-year median for Payables is $4.4 million (2023), against an average of $5.7 million.
  • The largest annual shift saw Payables tumbled 61.71% in 2023 before it soared 233.01% in 2024.
  • A 5-year view of Payables shows it stood at $4.0 million in 2021, then grew by 5.7% to $4.2 million in 2022, then rose by 24.98% to $5.3 million in 2023, then skyrocketed by 31.62% to $6.9 million in 2024, then surged by 101.63% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Payables are $13.9 million (Q3 2025), $13.4 million (Q2 2025), and $12.4 million (Q1 2025).